Baculoviral IAP repeat-containing protein 7 (BIRC7) peptide-MHC class I complex (BIRC7-MHC I)

Baculoviral IAP repeat-containing protein 7 (BIRC7), commonly known as Livin or Melanoma inhibitor of apoptosis protein (ML-IAP), is a potent anti-apoptotic protein frequently overexpressed in a variety of cancers, including melanoma, lung cancer, and leukemia, while remaining largely absent in normal adult tissues (UniProt O43663). Peptides derived from the Livin protein are processed by the proteasome and presented on the cell surface by Major Histocompatibility Complex (MHC) class I molecules, most notably HLA-A*02:01 (PubMed: 15150595). These peptide-MHC complexes serve as specific tumor-associated antigens that can be recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes. Therapeutic approaches targeting these complexes include peptide-based vaccines designed to elicit a cytotoxic T lymphocyte (CTL) response and the development of T-cell receptor (TCR) engineered T cells (PubMed: 11447167). Because Livin expression is highly tumor-specific, these complexes represent attractive targets for precision immunotherapy with a potentially favorable safety profile. Clinical studies have explored the immunogenicity of Livin-derived peptides like VLPFEILLI to treat melanoma and other solid tumors (PubMed: 21814174).

Other names

Livin peptide-MHC complexML-IAP peptide-HLA complexBIRC7-derived epitopeLivin-derived peptide-MHC class IMelanoma inhibitor of apoptosis protein peptide-MHC complex

Induction of peptide-specific cytotoxic T lymphocyte (CTL) responses against tumor cells presenting the Livin-derived peptide on MHC class I molecules.